300+ investors in your industry, stage, and region Get
Any industry
Artificial Intelligence
Google
EdTech
Clean Energy
Retail
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Social Impact
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Organic Food
Email
Fitness
CleanTech
Energy
Health Care
Machine Learning
Agriculture (AgTech)
Marketplace
Gaming
Facebook
Blockchain
B2B
Social Network
Big Data
Video Games
Education
Wellness
Medical Device
Mobile
Construction
Automotive
Legal
Sports
eSports
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Theatre
Recruiting
Crowdfunding
Web3
Medical
Fashion
Social
Venture Capital
Infrastructure
Beauty
Celebrity
Cannabis
Climate
LGBT
Publishing
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Music
Real Estate
Art
Sporting Goods
Digital Media
Finance
Manufacturing
FinTech
Social Media
Financial Services
Franchise
Non Profit
Mobile Advertising
Internet
Android
Biotech
Proptech
Sustainability
Hardware
Transportation
Impact
Enterprise
Community
Media (Entertainment)
Any country
Burkina Faso
South Korea
Africa
LATAM
Singapore
Brazil
Saudi Arabia
Oceania
Greece
Gibraltar
Norway
Liberia
Mexico
Taiwan
Sweden
Zambia
Puerto Rico
Tunisia
Russian Federation
Togo
Tajikistan
Zimbabwe
Nigeria
Guinea
Nepal
Iran
Kyrgyzstan
Isle of Man
Romania
Pakistan
Cameroon
Oman
New Zealand
Colombia
Australia
China
Sri Lanka
Armenia
Costa Rica
Switzerland
Czech Republic
Cayman Islands
Kenya
Kuwait
Kazakhstan
Jamaica
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uganda
Turkey
Uzbekistan
Venezuela
Guatemala
Malawi
Seychelles
Moldova
Botswana
United Kingdom
Japan
South Africa
Egypt
France
Georgia
Denmark
Croatia
Hong Kong
Ghana
Iraq
Mali
Morocco
Myanmar
Latvia
Malaysia
Poland
Philippines
Portugal
Sierra Leone
Rwanda
El Salvador
Senegal
Thailand
Uruguay
Tanzania
India
Germany
Canada
United States
Ireland
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Cyprus
Qatar
United Arab Emirates
Spain
Europe
Angola
Argentina
Bangladesh
Barbados
Belgium
Ethiopia
Jordan
Austria
Azerbaijan
Ecuador
Bulgaria
Bahrain
Bahamas
Faroe Islands
Jersey
Estonia
Bolivia
Algeria
Belize
Belarus
Finland
Italy
Hungary
Israel
Grenada
Honduras
Iceland
Cambodia
Lithuania
Liechtenstein
Lebanon
Mongolia
San Marino
Peru
Slovenia
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Download Find emails Save list
Open database

Top 50 Life Science VC Funds & Investors in Belgium (July 2026)

The most active venture capital funds investing in Belgium Life Science startups. This investor list is updated monthly from the Shizune investor database, ranked by number of investments in Belgium Life Science startup companies. Find investors to raise a Seed, Series A or Series B round with Shizune.
Investor Relevant Deals Geography Stage Focus Round Size
Meusinvest (Noshaq)
VC Fund
7 Belgium, France, Germany Series A, Seed Biotechnology, Health Care, Medical $137k–$16M
PMV
VC Fund
5 Belgium, United States, The Netherlands Series A, Seed Software, Biotechnology, Health Care $549k–$40M
Qbic Fund
VC Fund
4 Belgium, The Netherlands Seed, Series A Biotechnology, Software, Health Care $868k–$28M
Sambrinvest
VC Fund
3 Belgium, France, Spain Seed, Series A, Series B Biotechnology, Health Care, Medical $411k–$46M
Limburgse Reconversie Maatschappij
VC Fund
3 Belgium, United States, The Netherlands Seed, Series A Information Technology, Software, Biotechnology $494k–$11M
S.R.I.W.
VC Fund
3 Belgium, United States, Spain Series A, Series B Health Care, Biotechnology, Manufacturing $411k–$75M
Theodorus III
VC Fund
2 Belgium, Canada, France Seed, Series A Health Care, Life Science, Biotechnology $2.2M–$18M
Innovation Fund
VC Fund
2 Belgium, France, Luxembourg Seed, Series A Health Care, Manufacturing, Information Technology $329k–$5.8M
VIB
VC Fund
2 Belgium, Brazil, Denmark Series A, Series B, Seed Biotechnology, Health Care, Therapeutics $3.1M–$84M
V-Bio Ventures
VC Fund
2 Belgium, France, United States Series A, Series B, Seed Biotechnology, Health Care, Therapeutics $3.1M–$88M
Mérieux Equity Partners
VC Fund
2 France, United States, Belgium Series A, Private Equity Health Care, Biotechnology, Medical Device $5.7M–$150M
Qbic
VC Fund
1 Belgium Seed, Series B Health Care, Biotechnology, AgTech
European Circular Bioeconomy Fund
VC Fund
1 Germany, France, The Netherlands Series A, Series B, Venture - Series Unknown Biotechnology, AgTech, Agriculture $4.4M–$43M
Innovation Industries
VC Fund
1 The Netherlands, Belgium, United States Seed, Series A Semiconductor, Manufacturing, Electronics $2M–$33M
European Investment Bank
VC Fund
1 France, Germany, The Netherlands Debt Financing, Post-IPO Debt Biotechnology, Health Care, Energy $16M–$658M
Vives Louvain Technology Fund
VC Fund
1 Belgium, France, United States Series A, Series B Health Care, Biotechnology, Medical $491k–$125M
Samsara BioCapital
VC Fund
1 United States, United Kingdom, Canada Series B, Series A, Post-IPO Equity Biotechnology, Health Care, Therapeutics $33M–$200M
Regeneron Ventures
VC Fund
1 United States, Belgium Series A, Series B, Series C Biotechnology, Biopharma, Health Care $40M–$175M
New Science Ventures
VC Fund
1 United States, United Kingdom, Belgium Series B, Series A, Series D Biotechnology, Health Care, Medical $4M–$52M
Newton Biocapital
VC Fund
1 Belgium, Japan, France Series A, Seed Biotechnology, Medical, Health Care $2.7M–$84M
Smedvig
VC Fund
1 Belgium, Romania, South Africa Series A, Series C Mining, Medical, Software
Fund+
VC Fund
1 Belgium, United States, Spain Series A, Series B, Series C Biotechnology, Health Care, Therapeutics $11M–$401M
Forbion Capital Partners
VC Fund
1 United States, United Kingdom, The Netherlands Series B, Series A, Series C Biotechnology, Health Care, Medical $16M–$176M
Sofinnova Investments
VC Fund
1 United States, France, Switzerland Series B, Series A, Series C Biotechnology, Health Care, Pharmaceutical $7.3M–$150M
Luma Group
VC Fund
1 United States, Belgium Series A, Series B, Series C Biotechnology, Health Care, Biopharma $40M–$125M
the SRIW Life Sciences
VC Fund
1 Belgium Series A, Series B Biotechnology, Medical, Biopharma $21M–$26M
Industrya
VC Fund
1 France, Belgium Seed, Series A Industrial, B2B, SaaS $1M–$6.7M
OBI SA
VC Fund
1 Belgium Life Science, Biotechnology, Health Diagnostics
Capricorn Partners
VC Fund
1 Belgium, The Netherlands, United States Series A, Series B Biotechnology, Software, Health Care $3.3M–$42M
Seventure Partners
VC Fund
1 France, United States, Germany Series A, Series B Biotechnology, Health Care, Software $3.1M–$65M
Novo Nordisk
VC Fund
1 United States, Denmark, Canada Series A, Seed, Series B Biotechnology, Health Care, Therapeutics $1.6M–$115M
6K Venture Capital
VC Fund
1 Panama, Belgium Seed, Series A Medical, Software, Health Care
WING by Digital Wallonia
VC Fund
1 Belgium Seed, Series A, Convertible Note Software, Health Care, Information Technology $219k–$11M
Epimède SA
VC Fund
1 Belgium, The Netherlands Series B, Series C, Series D Biotechnology, Medical, Health Care $12M–$23M
Korys
VC Fund
1 Belgium, The Netherlands, Germany Series B, Series A Biotechnology, Renewable Energy, Information Technology $3.9M–$50M
UCB Ventures
VC Fund
1 United States, Belgium, Spain Series A, Series B, Seed Biotechnology, Health Care, Medical $1.8M–$135M
SFPI-FPIM
VC Fund
1 Belgium, United States, The Netherlands Series B, Series A Health Care, Biotechnology, Medical $4.4M–$75M
BioGeneration Ventures
VC Fund
1 The Netherlands, United States, Belgium Series A, Seed Biotechnology, Therapeutics, Health Care $1.1M–$86M
Nivelinvest
VC Fund
1 Belgium, United States Series A, Seed Biotechnology, iOS, Sports $6.6M–$31M
Nausicaa Ventures
VC Fund
1 Belgium Series B Software, CRM, Big Data
Fonds Vives II (University of Louvain, UCL)
VC Fund
1 Belgium, United States Series A, Series B, Seed Biotechnology, Health Care, Medical $6.6M–$75M
VIVES Funds
VC Fund
1 Belgium, France, Switzerland Seed, Series A, Series B Biotechnology, Health Care, Therapeutics $2.9M–$132M
Ifoghas Investments
VC Fund
1 Belgium Series A Medical, Health Care, Life Science
Longwood Fund
VC Fund
1 United States, United Kingdom, Italy Series A, Series B, Series C Biotechnology, Therapeutics, Health Care $16M–$152M
Galapagos
VC Fund
1 France, Belgium, United States Seed, Series A, Series C Biotechnology, Health Care, Life Science $52M–$125M
Finchley Healthcare Ventures
VC Fund
1 United States, Belgium Series B, Series A Biotechnology, Biopharma, Life Science $67M–$120M
Balyasny Asset Management
VC Fund
1 United States, China, Sweden Series D, Series A, Series C Biotechnology, FinTech, Analytics $6.1M–$350M
Novo Holdings
VC Fund
1 United States, Denmark, United Kingdom Series A, Series B, Series C Biotechnology, Health Care, Medical $9M–$135M
invest.bw
VC Fund
1 Belgium, United States Seed, Pre-Seed, Series A Electronics, Biotechnology, Manufacturing $2.9M–$43M
Opdorp Finance BVBA
VC Fund
1 Belgium Series A Life Science, Data Integration, Data Visualization
Access all 62 VC funds in Belgium Life Science startups.

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Investor list

Meusinvest (Noshaq)
VC Fund · Liège, Liege, Belgium · 7 investments in Belgium Life Science startups

Noshaq offers financial services to help businesses develop.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Seed
  • Geography: Belgium, France, Germany

Investor stats

  • Total investments: 77
  • Round size: Seed $137k–$6M; Series A $3.3M–$16M
  • Lead/follow: 9% lead, 91% follow

Portfolio highlights

  • TrustUp — TrustUp is the home contractors platform, connects homeowners with verified quality home improvement.
  • Le Fourgon — Le Fourgon provides contained drinks for home delivery. They offer milk, water, beer, wine, fruit juice, and sodas. They allow customers to have their drinks delivered free of charge during the day.
  • Allegro Biotech — Allegro has developed the world’s-first custom-tailored, durable, biocompatible, anisotropic, regenerative meniscus cartilage, providing immediate support while also leverage the body’s own healing potential to regenerate human cartilage (proliferation and differentiation of fibrochondrocyte cells).
Show all investments...

PMV
VC Fund · Brussels, Brussels Hoofdstedelijk Gewest, Belgium · 5 investments in Belgium Life Science startups

Do and dare company

Show more...

Investment focus

  • Industry: Software, Biotechnology, Health Care
  • Stage:Series A, Seed
  • Geography: Belgium, United States, The Netherlands

Investor stats

  • Total investments: 152
  • Round size: Seed $549k–$4.3M; Series A $2.7M–$40M
  • Lead/follow: 22% lead, 78% follow

Portfolio highlights

  • Animab — Animal Health Company
  • Sentea — Sentea makes fibre optic Sensing affordable to the industry and enables continuous monitoring even in harsh environments.
  • CHILI publish — Allow users to edit customizable documents, or fully automate artwork generation. Output files are ready to use for print and digital.
Show all investments...

Qbic Fund
VC Fund · Belgium, Wisconsin, United States · 4 investments in Belgium Life Science startups

The Qbic Fund is a multi-sector fund supporting spin-off companies of the Ghent, Brussels and Antwerp university associations and of VITO. Through its strategic partnership with the universities of Ghent, Brussels and Antwerp, and VITO, the Qbic Fund has early and privileged access to promising research projects at these partner universities. Ourinvestment approach is based on early in-depth and independent review and analysis followed by hands on involvement and support.In May 2012 the Qbic Fund held its first close and currently it has over € 30 million under management. The Qbic Fund is backed by several public and private investors and managed by Qbic Venture Partners.

Show more...

Investment focus

  • Industry: Biotechnology, Software, Health Care
  • Stage:Seed, Series A
  • Geography: Belgium, The Netherlands

Investor stats

  • Total investments: 57
  • Round size: Seed $1.3M–$7.7M; Series A $868k–$28M
  • Lead/follow: 28% lead, 72% follow
  • Last fund: Likely still investing — raised $57M in 2022

Portfolio highlights

  • Aloxy — Aloxy offers reliable IIot solutions tailored to the needs of the process industry. Our valve sensor provides an open and close indication of manual valves.
  • Accelleran — Accelleran is pioneering a disruptive approach to the delivery of cost-effective, carrier and mission-critical grade TDD and FDD Small Cell networks through its focus on software quality and partnerships with volume manufacturers.Accelleran provides LTE Small Cell software and LTE Small Cell product solutions which address the real-worldchallenges of volume deployment of Small Cells. We offer turnkey solutions and unique experience on the challenges of integrating cellular technology on low cost, yet powerful platforms and architectures. Accelleran offers its customers solid and dependable system solutions, backed by the support of our unparalleled expertise.Accelleran’s technology is genuinely independent from any HW platform and enables operators to invest once in the integration and validation of a common software base that can be deployed across different segments, platforms and Small Cell architectural approaches to enable a truly integrated HetNet.
  • Blue Foot Membranes — Blue Foot Membranes delivers unbreakable MBR membranes for wastewater treatment. Reliable water reuse, high capacity and low total cost of ownership.
Show all investments...

Sambrinvest
VC Fund · Gosselies, Hainaut, Belgium · 3 investments in Belgium Life Science startups

Sambrinvest is an active venture capital player in the region of Charleroi - Thuin.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Seed, Series A, Series B
  • Geography: Belgium, France, Spain

Investor stats

  • Total investments: 39
  • Round size: Seed $544k–$24M; Series A $411k–$46M; Series B $4.4M–$44M
  • Lead/follow: 10% lead, 90% follow

Portfolio highlights

  • Sunrise — Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems.
  • Vertical Compute — Vertical Compute offers chiplet-based technology that cuts data movement to achieve up to 80% energy savings.
  • Enodia Therapeutics — Enodia Therapeutics pioneers targeted protein degradation at the Sec61 translocon, developing small-molecule therapies for inflammatory and autoimmune diseases.
Show all investments...

Limburgse Reconversie Maatschappij
VC Fund · Hasselt, Limburg, Belgium · 3 investments in Belgium Life Science startups

Oxygen for growth - LRM

Show more...

Investment focus

  • Industry: Information Technology, Software, Biotechnology
  • Stage:Seed, Series A
  • Geography: Belgium, United States, The Netherlands

Investor stats

  • Total investments: 91
  • Round size: Seed $494k–$5.2M; Series A $1.6M–$11M
  • Lead/follow: 13% lead, 87% follow

Portfolio highlights

  • Monsana — Monsana offers an AI-powered platform that connects eligible participants to relevant clinical trials throughout Europe.
  • ADLC — ADLC employs drone technology to deliver logistics services, allowing businesses to implement drone-based solutions without having to manage them in-house. The company is focused on enhancing last-mile delivery in maritime and offshore environments. ADLC now conducts drone delivery services in the Port of Antwerp in collaboration with SGS, atesting and certification company, and works with companies such as BASF. Its drones have reduced delivery times and environmental effect, boosting efficiency sixfold and lowering CO2 emissions by up to 80% for petrochemical sample deliveries.
  • Aidoptation — Aidoptation develops autonomous driving technology for dual-use applications in commercial automotive, police and first-responder vehicles, and defence-relevant environments.
Show all investments...

S.R.I.W.
VC Fund · Liège, Liege, Belgium · 3 investments in Belgium Life Science startups

The S.R.I.W. Group is an institution at the heart of the financial market that assists entrepreneurs in creating and developing businesses in the Walloon region. It reflects the effort of Wallonian industry in facing the challenges of the creation of economic value in the 21st century. Since its creation in 1979, the Société Régionaled’Investissement de Wallonie has continuously been expanding its abilities to adapt and anticipate as well as its flexibility in order to meet the requirements of its partners who are confronted with the evolution of the world economy. The principles of good governance, a strong business culture and shared values at the heart of the Group constitute important assets to capture the changing realities of the market and progress in a sustainable development perspective.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Manufacturing
  • Stage:Series A, Series B
  • Geography: Belgium, United States, Spain

Investor stats

  • Total investments: 111
  • Round size: Series A $411k–$31M; Series B $1.6M–$75M
  • Lead/follow: 21% lead, 79% follow

Portfolio highlights

  • Univercells — We are biotech innovators, rooted in Belgium, driven by one purpose: To transform how biotech drugs are made so everyone, everywhere, can get them.
  • Intressa Vascular — Intressa Vascular provides innovative solutions to address life-threatening cardiovascular conditions such as aortic dissection.
  • Santero Therapeutics — This is the homepage of the website
Show all investments...

Theodorus III
VC Fund · 2 investments in Belgium Life Science startups

Theodorus is the spin-off fund of Université Libre de Bruxelles that invests ininvest in early stage projects based on proprietary disruptive technologies.

Show more...

Investment focus

  • Industry: Health Care, Life Science, Biotechnology
  • Stage:Seed, Series A
  • Geography: Belgium, Canada, France

Investor stats

  • Total investments: 15
  • Round size: Seed $3.7M–$18M; Series A $2.2M–$6.6M
  • Lead/follow: 20% lead, 80% follow

Portfolio highlights

  • DrugBank — DrugBank augments human intelligence to improve the world’s health. Our suite of products are powered by the world’s most complete and up-to-date pharmaceutical knowledge database. It includes everything there is to know about drugs and how they work in the body. We enable companies to improve healthcare delivery through precision medicine orclinical software applications, as well as uncover insights through data science in drug discovery. Our knowledge base can be integrated into software solutions to help achieve clinical intelligence. Companies can easily scale their usage through our API and launch faster with flexible data modules. By providing users with advanced insights and the right information at the right time, users are empowered to make better health decisions.Our extensive, structured datasets are used to discover novel drug candidates, identify drug repurposing opportunities, and build predictive machine learning models. Companies working with data science can find answers quickly and get drugs to market faster with our evidence-based drug information. Lastly, our publicly available resource, DrugBank Online, is free-to-use with limited datasets available for download for academic and non-commercial researchers. DrugBank has been cited in over 13,000 academic publications and is used by millions of researchers and health professionals globally.
  • Simmunome AI — We use AI to create accurate, comprehensive disease models using multi-omic data to determine the probability of success of a drug. Our clinical trial simulations allow you to gain insights, make go/no-go decisions, and de-risk your pipeline, getting you to market faster and reducing your R&D co
  • Ability biologics — Ability develops innovative, targeted, immune modulating biotherapeutics to address unmet medical needs in patients with cancer and autoimmune diseases.
Show all investments...

Innovation Fund
VC Fund · Brussels, Brussels Hoofdstedelijk Gewest, Belgium · 2 investments in Belgium Life Science startups

Chemical, Advanced Materials, Cosmetics, Recycling, CleanTech, Plastics and Rubber Manufacturing, Nanotechnology, Biosciences

Show more...

Investment focus

  • Industry: Health Care, Manufacturing, Information Technology
  • Stage:Seed, Series A
  • Geography: Belgium, France, Luxembourg

Investor stats

  • Total investments: 30
  • Round size: Seed $329k–$5.8M; Series A $2.2M–$5.7M
  • Lead/follow: 27% lead, 73% follow

Portfolio highlights

  • Aerosint — Aerosint invented a technology called "Selective Powder Deposition" which deposits multiple powders in each layer. This unlocks multi-material 3D printing.
  • Daphne Technology — Measure and abate methane slip with Daphne Technology. Learn how we reduce emissions in gas engine exhaust. Contact us today!
  • Zeopore Technologies — Zeopore Technologies innovates zeolite mesoporization to optimize catalysts that enhance processes in refining and petrochemical industries. This leads to higher quality products, lower energy use and less waste, using an approach that is affordable, easily scalable and non-hazardous.
Show all investments...

VIB
VC Fund · Gent, Oost-Vlaanderen, Belgium · 2 investments in Belgium Life Science startups

Strategic research in on life sciences and biotechnology

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Seed
  • Geography: Belgium, Brazil, Denmark

Investor stats

  • Total investments: 24
  • Round size: Seed $3.1M–$4.6M; Series A $6.8M–$84M; Series B $4.4M–$65M
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Animab — Animal Health Company
  • Biotalys — Biotalys is an Agricultural Technology (AgTech) company that employs its proprietary Agrobody technology platform to develop crop and food protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combinethe high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications.It was incorporated in 2013 and is based in the Biotech hub in Ghent, Belgium.
  • MRM Health NV — MRM Health NV, is a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome. MRM Health was incorporated early 2020 by MRM Technologies, a Center of Expertise for microbiome research based in the biotech cluster in Ghent, in a joint venture with the Flemish Institute ofBiotechnology (VIB), an excellence-based entrepreneurial life sciences research institute in Flanders, Belgium, that focuses on translating basic scientific results into pharmaceutical, agricultural and industrial applications.
Show all investments...

V-Bio Ventures
VC Fund · Gent, Oost-Vlaanderen, Belgium · 2 investments in Belgium Life Science startups

V-Bio Ventures is an independent venture capital firm specialized in building and financing young, innovative life science companies. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biotech, pharmaceutical and agriculturalsectors.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Seed
  • Geography: Belgium, France, United States

Investor stats

  • Total investments: 43
  • Round size: Seed $3.1M–$50M; Series A $6.6M–$70M; Series B $12M–$88M
  • Lead/follow: 35% lead, 65% follow
  • Last fund: May invest from a new fund soon — raised $129M in 2021

Portfolio highlights

  • Animab — Animal Health Company
  • Step Pharma — Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe.
  • Biodol Therapeutics — Biodol Therapeutics, founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified the Receptor Tyrosine Kinase (RTK) FLT3 as a key player for triggering and maintaining the chronic neuropathic pain (NP) state. New findings from Biodol Therapeutics' academic partnership (CyrilRivat and Jean Valmier at the INSERM Institute for Neurosciences in Montpellier) also demonstrated that FLT3 inhibition increases the potency of opioids for their analgesic effect, and hereby reduces their safety risks, especially addiction risk, which will help fighting the Opioid Crisis. The development of extracellular inhibitors of the FLT3 receptor, is a proprietary and key approach developed by Biodol Therapeutics.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Mérieux Equity Partners
VC Fund · Lyon, Rhone-Alpes, France · 2 investments in Belgium Life Science startups

Mérieux Equity Partners (“MxEP”) is a management company dedicated to venture, growth and LBO investments in the healthcare and nutrition sectors. MxEP actively supports entrepreneurs and industrial companies with differentiated products and services, by providing privileged access to its expertise and international network. MxEP currently managesmore than €600m AUM and has recently launched a new vehicle MP3 of €350m dedicated to growth/LBO.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical Device
  • Stage:Series A, Private Equity
  • Geography: France, United States, Belgium

Investor stats

  • Total investments: 57
  • Round size: Series A $5.7M–$22M; Private Equity $22M–$150M
  • Lead/follow: 37% lead, 63% follow
  • Last fund: May invest from a new fund soon — raised $417M in 2020

Portfolio highlights

  • DeepUll — DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition. DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functionalstatus on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise.
  • Ceva Santé Animale — Ceva Sante Animale S.A. engages in the research, development, production, and marketing of pharmaceutical products and vaccines for companion and farm animals. They work with welfare and social programmes around the world to bring this vision to life – anywhere their products and know-how can make a difference and with all kinds of partners. FromUganda, working with small-scale livestock owners and vets to stop sleeping sickness in its tracks, to the UK and USA, where they supply the biggest animal welfare charities with Adaptil® collars to help re-home shelter dogs.
  • CorFlow Therapeutics — CorFlow Therapeutics is a medtech startup that develops proprietary technologies for diagnosis and treatment of microvascular obstructions in heart attack patients. The CorFlow technologies enable interventional cardiologists to diagnose and treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complicationrates in these patients.
Show all investments...

Qbic
VC Fund · London, England, United Kingdom · 1 investments in Belgium Life Science startups

Qbic is the result of a lot of thinking, debating and sketching of what a city hotel could be; one that breaks the rules and makes people smile.An astonishing level of change has swept through the world over the last few years. But the hotel experience is no different than it’s ever been: stuffy, over-priced and lacking soul. They’re here tochange all that. they’re curious, imaginative and friendly, and they think there are lots of people just like us seeking a hotel with personality in the middle of the city.They believe in something better than what’s currently out there. A place that celebrates life rather than sucks life out of it. A hotel that’s built on creativity and a belief that you don’t have to accept the conventional. Somewhere that sends you away with fun stories and ideas, and is easy on your pocket.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, AgTech
  • Stage:Seed, Series B
  • Geography: Belgium

Investor stats

  • Total investments: 7
  • Lead/follow: no public data

Portfolio highlights

  • moveUP — Ontvang medische zorg op afstand voor en na uw operatie. moveUP is gespecialiseerd in de begeleiding van knie- en heupoperaties.
  • Axithra — Axithra provides therapeutic medication monitoring and measures beta-lactam antibiotic concentrations in blood.
  • Cascador Health — Cascador Health bridges the gap between sources and users of healthcare data. Using curated, validated and anonymized RWD allows healthcare providers and life science industry to gain insights and provide better care.
Show all investments...

European Circular Bioeconomy Fund
VC Fund · Bonn, Nordrhein-Westfalen, Germany · 1 investments in Belgium Life Science startups

The specialist VC for a regenerative economy

Show more...

Investment focus

  • Industry: Biotechnology, AgTech, Agriculture
  • Stage:Series A, Series B, Venture - Series Unknown
  • Geography: Germany, France, The Netherlands

Investor stats

  • Total investments: 24
  • Round size: Series A $4.7M–$30M; Series B $4.4M–$43M; Venture - Series Unknown $8.7M–$20M
  • Lead/follow: 71% lead, 29% follow
  • Last fund: Likely still investing — raised $351M in 2022

Portfolio highlights

  • AmphiStar — We are developing a proprietary technology platform for the ecological production of biosurfactants, that are clean, safe, sustainable and biodegradable
  • Biosyntia — Biosyntia is a biotech startup within synthetic biology and metabolic engineering. We develop biocatalysts at an unprecedented speed and efficiency by employing our patent pending high-throughput screening technology.By developing tailored processes based on biocatalysis, Biosyntia enables production of complex chemical compounds byfermentation. Biocatalysis may substantially reduce both production costs and environmental impact compared to other processes such as chemical synthesis. We partner with manufacturers of fine chemical compounds (flavors, fragrances, APIs, pigments, additives, intermediates, and more) in order to establish more sustainable manufacturing processes for a greener tomorrow.Biosyntia is located at the Novo Nordisk Foundation (NNF) Center for Biosustainability in Hørsholm, 25 kilometers north of Copenhagen.
  • Elicit Plant — We work with farmers around the world to meet the challenges of climate change and the impact of water scarcity on field crops.
Show all investments...

Innovation Industries
VC Fund · Amsterdam, Noord-Holland, The Netherlands · 1 investments in Belgium Life Science startups

Innovation Industries is a Dutch venture capital fund investing in impactful deep tech, focusing on sustainability, scalability, and ESG-aligned companies.

Show more...

Investment focus

  • Industry: Semiconductor, Manufacturing, Electronics
  • Stage:Seed, Series A
  • Geography: The Netherlands, Belgium, United States

Investor stats

  • Total investments: 76
  • Round size: Seed $2M–$12M; Series A $11M–$33M
  • Lead/follow: 51% lead, 49% follow
  • Last fund: Likely still investing — raised $204M in 2023

Portfolio highlights

  • Eyeo — eyeo revolutionizes imaging with color splitter sensors. Capture sharper, brighter images in low light using optical waveguide innovation, discover how it works
  • Orbem — Transform biological imaging with AI-powered MRI technology. Non-invasive solutions for poultry, fruits, nuts, and health. Building a sustainable future.
  • Groove Quantum — Our expert team advances quantum computing by developing scalable germanium qubits, integrating seamlessly with semiconductor processes.
Show all investments...

European Investment Bank
VC Fund · Luxembourg, Luxembourg, Luxembourg · 1 investments in Belgium Life Science startups

The European Investment Bank (EIB) offers lending, borrowing, and treasury services primarily within the European Union. It provides project loans for public and private sectors, loans to banks and intermediaries, structured finance products, guarantees, and securitization instruments for debts. Additionally, EIB offers equity and fund investmentproducts, including infrastructure and environmental funds, as well as venture capital funds. EIB also supports microfinance and risk-sharing finance for research and innovation, and provides technical expertise for sustainable energy projects. Its services include infrastructure advisory, urban development support, guarantees for transport infrastructure, and funding for public-private partnerships and small- to medium-sized enterprises. The bank serves various sectors, including transportation, energy, health, education, and agriculture.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Energy
  • Stage:Debt Financing, Post-IPO Debt
  • Geography: France, Germany, The Netherlands

Investor stats

  • Total investments: 358
  • Round size: Post-IPO Debt $18M–$658M; Debt Financing $16M–$384M
  • Lead/follow: 80% lead, 20% follow

Portfolio highlights

  • Icosagen Group — Icosagen is an end-to-end Contract Research, Development & Manufacturing Organization. A science-driven partner for antibody, protein & biologics solutions.
  • Wandercraft — Self- balancing and hands free movement with the innovative self-balancing feature, Atalante allows for multi-tasking and cognitive involvement as part of treatments.
  • IPT PowerTech — IPT PowerTech coverage, coupled with our extensive expertise in supply chain management, field implementation, and power systems, has made us one of the most capable companies in handling the most complicated and versatile projects in the MEA region and its neighboring countries.
Show all investments...

Vives Louvain Technology Fund
VC Fund · Louvain-la-neuve, Vlaams-Brabant, Belgium · 1 investments in Belgium Life Science startups

Vives is an interregional seed and early stage technology multi-sector fund. The new fund, initiated by UCLouvain, is a unique European inter-university fund having access to world class innovations from leading EU top universities.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series A, Series B
  • Geography: Belgium, France, United States

Investor stats

  • Total investments: 25
  • Round size: Series A $491k–$46M; Series B $4.4M–$125M
  • Lead/follow: 4% lead, 96% follow
  • Last fund: May invest from a new fund soon — raised $37M in 2020

Portfolio highlights

  • BOTALYS — BOTALYS uses an innovative Biomimetic Indoor Farming technology to recreate the ideal wild conditions for rare botanicals to grow in. We develop pristine & potent botanical ingredients for the Nutraceutical and Cosmetic industries.
  • Sunrise — Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems.
  • Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
Show all investments...

Samsara BioCapital
VC Fund · Palo Alto, California, United States · 1 investments in Belgium Life Science startups

Samsara Biocapital provides investment advisory services to help entrepreneurs turn their own ideas and visions into successful companies. Samsara BioCapital, as a results-driven organization, is always looking for ambitious and visionary partners with the drive and flexibility to take their company to the next level. Samsara BioCapital promotesbiotech innovation and collaborates with inspiring companies as they develop important and innovative new therapies.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series B, Series A, Post-IPO Equity
  • Geography: United States, United Kingdom, Canada

Investor stats

  • Total investments: 174
  • Round size: Series A $42M–$200M; Series B $33M–$200M; Post-IPO Equity $40M–$200M
  • Lead/follow: 15% lead, 85% follow

Portfolio highlights

  • Ionpath — Ionpath is a developer of an ion beam imaging technology used to provide analysis of tissue biopsies. Its imaging technology surpasses light microscopy to analyze whether the tissues are fresh, frozen, or FFPE that enable healthcare providers to provide a diagnosis of cancer for improving human health.
  • Normunity — We create medicines that free normal immunity to defeat cancer using proprietary platforms that uncover novel immuno-oncology mechanisms.
  • Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
Show all investments...

Regeneron Ventures
VC Fund · 1 investments in Belgium Life Science startups

Regeneron Ventures is a health care venture capital fund.

Show more...

Investment focus

  • Industry: Biotechnology, Biopharma, Health Care
  • Stage:Series A, Series B, Series C
  • Geography: United States, Belgium

Investor stats

  • Total investments: 16
  • Round size: Series A $48M–$135M; Series B $40M–$175M
  • Lead/follow: 25% lead, 75% follow

Portfolio highlights

  • Think Bioscience — Think Bioscience is reimagining synthetic biology by guiding the design and assembly of better medicines through the use of living systems.
  • City Therapeutics — City Therapeutics is a biopharmaceutical company focusing on engineering next-generation small-interfering RNAs (siRNAs) to enhance RNAi-based therapies. The company develops a pipeline of innovative RNAi therapeutics aimed at addressing various disease indications. City Therapeutics prioritizes improving and expanding RNAi technology to achievebetter patient outcomes. The leadership team includes experienced scientists and industry professionals dedicated to advancing the field of RNA interference.
  • Coultreon Biopharma — Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.Coultreon Biopharma employs extensive experience in disease biology, drug development, and translational science to identify the optimum treatment approach for addressing underlying illness biology withbest-in-class therapeutics.
Show all investments...

New Science Ventures
VC Fund · New York, New York, United States · 1 investments in Belgium Life Science startups

New Science Ventures is a venture capital firm that focuses on investments in life sciences and information technology companies. They invest in early and late stage companies taking novel scientific approaches to address significant unmet needs, while creating order-of-magnitude improvements in performances. The company also invests in companiesusing science-based innovations to address market needs in life sciences such as pharmaceuticals, biologics, medical devices, diagnostics, and IT. The team of the company expertise in strategy and corporate planning, operations and cost management, and leadership development.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series B, Series A, Series D
  • Geography: United States, United Kingdom, Belgium

Investor stats

  • Total investments: 85
  • Round size: Series A $4M–$49M; Series B $8M–$52M; Series D $5M–$38M
  • Lead/follow: 36% lead, 64% follow
  • Last fund: May invest from a new fund soon — raised $4.9M in 2020

Portfolio highlights

  • EXTEN Technologies — EXTEN HyperDynamic software platform solves the primary challenges of today's data centers: the necessity of keeping up with surging data density, velocity, and volume requirements, and the need for increased application agility.
  • BrightVolt — BrightVolt is an innovative manufacturer of solid-state thin & flexible lithium polymer batteries and power-efficient thin & flexible microelectronics for IoT clients. It specializes in the fields of battery, electronics, and manufacturing. BrightVolt got recapitalization in November 13, 2013.
  • Phase Four — Phase Four is a provider of electric propulsion (EP) for small satellites.The company was founded in 2015 to accelerate the advancement of its core differentiator, the Radio Frequency Thruster (RFT). The hallmark of Phase Four’s RFT is simplicity. Because the RFT omits a hollow cathode and high voltage electronics, three key improvements arerealized: 1) a 10x materials cost savings versus legacy EP systems, 2) a significant decrease in the size of power electronics, and 3) propellant agnosticism. In a first for EP, the Phase Four RF thruster accomplishes this while achieving performance in the same thrust, specific impulse (Isp), and efficiency class as legacy plasma propulsion solutions.
Show all investments...

Newton Biocapital
VC Fund · Brussels, Brussels Hoofdstedelijk Gewest, Belgium · 1 investments in Belgium Life Science startups

Our mission is to mature innovation and support the growth of our portfolio companies to create value for patients, society, local ecosystems, and investors.

Show more...

Investment focus

  • Industry: Biotechnology, Medical, Health Care
  • Stage:Series A, Seed
  • Geography: Belgium, Japan, France

Investor stats

  • Total investments: 22
  • Round size: Seed $2.7M–$3.2M; Series A $6.1M–$84M
  • Lead/follow: 68% lead, 32% follow
  • Last fund: Likely still investing — fund raised in 2022

Portfolio highlights

  • Bioxodes — Bioxodes is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics to prevent thrombotic events without hemorrhagic risk.
  • Tensegrity Pharma — Tensegrity Pharma is the developer of a novel drug designed to minimize bottlenecks and provide innovative value to patients.
  • Augustine Therapeutics — Augustine Therapeutics is developing selective, safe and efficacious HDAC6 inhibitors designed for treatment of neuromuscular, neurodegenerative and cardiometabolic diseases. Discover our pipeline poised for clinical impact.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Smedvig
VC Fund · Stavanger, Rogaland, Norway · 1 investments in Belgium Life Science startups

Venture Capital firm based in London. We help enable business funding though capital investment. In turn, that funds and drives business growth as exceptional speed. Visit our site to find out how our proven model of business investment can help your start up.

Show more...

Investment focus

  • Industry: Mining, Medical, Software
  • Stage:Series A, Series C
  • Geography: Belgium, Romania, South Africa

Investor stats

  • Total investments: 3
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Druid AI — DRUID is an AI platform that allows companies to automate processes by designing and deploying UiPath RPA integrated chatbot virtual assistants.
  • Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
  • Sedibelo Resources — Sedibelo Resources is a developing producer of platinum group metals (PGMs), is active in the acquisition, exploration for, and development and operation of deposits
Show all investments...

Fund+
VC Fund · Leuven, Vlaams-Brabant, Belgium · 1 investments in Belgium Life Science startups

Fund+ is a venture capital firm that invests in companies operating in the diagnostics, therapeutics, medical devices, and life science sectors. The firm wants to create sustainable shareholders' value, contribute to the development of a leadership position in the life sciences sector, and generate a tangible, beneficial societal impact.Fund+ was established in 2015 and is based in Leuven, Belgium.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Series C
  • Geography: Belgium, United States, Spain

Investor stats

  • Total investments: 32
  • Round size: Series A $11M–$44M; Series B $21M–$125M; Series C $11M–$401M
  • Lead/follow: 28% lead, 72% follow

Portfolio highlights

  • Ona Therapeutics — Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine.
  • Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
  • TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
Show all investments...

Forbion Capital Partners
VC Fund · Naarden, Noord-Holland, The Netherlands · 1 investments in Belgium Life Science startups

Impacting the future of medicine.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series B, Series A, Series C
  • Geography: United States, United Kingdom, The Netherlands

Investor stats

  • Total investments: 198
  • Round size: Series A $19M–$176M; Series B $16M–$155M; Series C $19M–$113M
  • Lead/follow: 52% lead, 48% follow
  • Last fund: Likely actively investing — fund raised in 2024

Portfolio highlights

  • Azafaros — Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.
  • Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
  • Gyroscope Therapeutics — Gyroscope is a clinical-stage gene therapy company focused on developing therapies and treating diseases of the eye.The company explores the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD), and gene therapy as a mode of treatmentdelivery. Its lead investigational gene therapy, GT005, is a one-time therapy delivered under the retina. GT005 is designed to restore balance to an overactive complement system by increasing the production of the Complement Factor I protein. GT005 is currently being evaluated in a Phase I/II clinical trial called FOCUS and Phase II clinical trials called EXPLORE and HORIZON.Andrew Lotery, David Kavanagh, and Peter Lachmann co-founded Gyroscope Therapeutics in Stevenage, Herefordshire in 2016.
Show all investments...

Sofinnova Investments
VC Fund · Menlo Park, California, United States · 1 investments in Belgium Life Science startups

Sofinnova deploys human and financial capital to turn dreams into drugs. We are a clinical-stage biopharmaceutical venture capital firm with approximately $2B in assets under management and committed capital.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Pharmaceutical
  • Stage:Series B, Series A, Series C
  • Geography: United States, France, Switzerland

Investor stats

  • Total investments: 217
  • Round size: Series A $7.3M–$115M; Series B $15M–$150M; Series C $15M–$94M
  • Lead/follow: 31% lead, 69% follow
  • Last fund: May invest from a new fund soon — raised $650M in 2016

Portfolio highlights

  • Invitae — Invitae and Labcorp together offer advanced genetic testing that can be easily integrated into medical practices. Improve patient care with meaningful insights based on DNA.
  • Vera Therapeutics — Vera Therapeutics is a biotechnology company developing innovative biologic therapeutics with transformative clinical potential. The company's gene-editing technology can potentially cure patients with sickle cell disease, cystic fibrosis, and other devastating genetic disorders, enabling physicians to improve gene detection and regulation.
  • Marinus Pharmaceuticals — Marinus Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to the development of ganaxolone, offering a new mechanism of action with demonstrated safety and convenient dosing for patients affected by epilepsy and CNS disorders.
Show all investments...

Luma Group
VC Fund · New York, New York, United States · 1 investments in Belgium Life Science startups

Fueling the future of human health and longevity with cutting edge innovations.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Biopharma
  • Stage:Series A, Series B, Series C
  • Geography: United States, Belgium

Investor stats

  • Total investments: 5
  • Round size: Series A $40M–$125M; Series B $55M–$93M
  • Lead/follow: 60% lead, 40% follow

Portfolio highlights

  • Curve Biosciences — Whole-Body Intelligence to resolve chronic diseases.
  • Coultreon Biopharma — Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.Coultreon Biopharma employs extensive experience in disease biology, drug development, and translational science to identify the optimum treatment approach for addressing underlying illness biology withbest-in-class therapeutics.
  • Aeovian Pharmaceuticals — Aeovian is a San Francisco based biopharmaceutical company developing novel and highly selective therapeutics modulating mTORC1 pathway.
Show all investments...

the SRIW Life Sciences
VC Fund · 1 investments in Belgium Life Science startups

the SRIW Life Sciences

Show more...

Investment focus

  • Industry: Biotechnology, Medical, Biopharma
  • Stage:Series A, Series B
  • Geography: Belgium

Investor stats

  • Total investments: 3
  • Round size: Series B $21M–$26M
  • Lead/follow: 33% lead, 67% follow

Portfolio highlights

  • A-Mansia Biotech — A-Mansia Biotech is a developer of products based on the properties of the Akkermansia muciniphila (A. muciniphila) bacterium. The company's nutritional supplement based on a gut bacterium called Akkermansia, the population of microorganisms housed in the gastrointestinal tract. A. muciniphila is located in the mucus layer covering theintestinal epithelium, which allows the bacterium to establish a close cross-talk with the host.
  • Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
Show all investments...

Industrya
VC Fund · Seraing, Liege, Belgium · 1 investments in Belgium Life Science startups

We are a hands-on investment fund that operates exclusively in the Industry 4.0, energy and new materials sectors. Industrya is an initiative of the John Cockerill industrial group, which joins together the investment funds of SFPI-FPIM, SRIW-WING, NOSHAQ and LRM.

Show more...

Investment focus

  • Industry: Industrial, B2B, SaaS
  • Stage:Seed, Series A
  • Geography: France, Belgium

Investor stats

  • Total investments: 12
  • Round size: Seed $1M–$4.4M; Series A $3.3M–$6.7M
  • Lead/follow: 33% lead, 67% follow

Portfolio highlights

  • Aloxy — Aloxy offers reliable IIot solutions tailored to the needs of the process industry. Our valve sensor provides an open and close indication of manual valves.
  • PureNat — PureNat is a deep-tech economy company that has developed a brand new patented biomimetic material for the purification of air and sustainable air pollution control solutions.
  • SupAirVision
Show all investments...

OBI SA
VC Fund · 1 investments in Belgium Life Science startups

OBI SA

Show more...

Investment focus

  • Industry: Life Science, Biotechnology, Health Diagnostics
  • Geography: Belgium

Investor stats

  • Total investments: 1
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Diagenode — Diagenode is an international life sciences company that develops and commercializes innovative instruments and reagents systems for life science research and molecular diagnostics. Founded in 2003 in Liege (Belgium), Diagenode is a global company, with headquarters in Liege, Belgium and Sparta, NJ, USA. Diagenode also has a local sales office inthe United Kingdom to better serve this specific country.Diagenode's customers include leading epigenetics researchers, academic institutions, high-profile genome centers and core labs, life sciences tools companies, molecular diagnostics players, and pharmaceutical and biotechnology companies.Epigenetics Division
Show all investments...

Capricorn Partners
VC Fund · Leuven, Vlaams-Brabant, Belgium · 1 investments in Belgium Life Science startups

Capricorn Partners is a unique independent manager of venture capital, growth capital and quoted equity funds

Show more...

Investment focus

  • Industry: Biotechnology, Software, Health Care
  • Stage:Series A, Series B
  • Geography: Belgium, The Netherlands, United States

Investor stats

  • Total investments: 118
  • Round size: Series A $3.3M–$18M; Series B $5.3M–$42M
  • Lead/follow: 32% lead, 68% follow
  • Last fund: Likely actively investing — fund raised in 2025

Portfolio highlights

  • Sensolus — Sensolus provides care-free tracking of your valuable non-powered assets directly from the cloud.Sensolus offers turnkey solutions for wireless, low-power context-aware sensing. Sensolus developed a personal product line of low-power tracker systems called STICKNTRACK.Sensolus is built upon many years of expertise in low-power networks,wireless sensor design, cloud-based sensor management, analytics, and applications.
  • Delft Advanced Biorenewables — We enable the bio-economy by improving the productivity of fermentations with our in-situ product recovery (ISPR) technology.
  • Trillium Renewable Chemicals — Trillium Renewable Chemicals manufactures chemicals from renewable feedstocks used in a variety of industrially important applications. The company was founded in 2021 and based in Knoxville, Tennessee.
Show all investments...

Seventure Partners
VC Fund · Paris, Ile-de-France, France · 1 investments in Belgium Life Science startups

Seventure Partners is a French venture capital firm targeting in Tech/Digital and Life Sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with € 1 billion undermanagement as of December 31, 2023. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.The different funds/verticals on which Seventure Partners are focusing on today: - Life Sciences : Biotech, Healthcare, Nutrition - Tech/Digital : B2B SaaS, Fintech, Retailtech, Cybersecurity - Sports & Wellbeing - Blue Economy

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Software
  • Stage:Series A, Series B
  • Geography: France, United States, Germany

Investor stats

  • Total investments: 238
  • Round size: Series A $3.1M–$27M; Series B $3.4M–$65M
  • Lead/follow: 35% lead, 65% follow
  • Last fund: May invest from a new fund soon — last raise in 2019

Portfolio highlights

  • Ekstere — Ekstere facilitates selling and purchasing verified-quality used bicycles at a reasonable price.
  • Pitchy — Create professional videos without technical expertise. Our online video editor helps you easily make business videos.
  • Aenitis Technologies — We develop innovative devices for cells therapy processing using Acoustic Radiation Forces.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Novo Nordisk
VC Fund · Bagsværd, Hovedstaden, Denmark · 1 investments in Belgium Life Science startups

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Seed, Series B
  • Geography: United States, Denmark, Canada

Investor stats

  • Total investments: 17
  • Round size: Seed $1.6M–$3.5M; Series A $5M–$17M; Series B $38M–$115M
  • Lead/follow: 47% lead, 53% follow

Portfolio highlights

  • Cellular Intelligence — Somite.ai is on a mission to transform the lives of millions of people by leveraging AI to produce human tissue for cell-based therapies.
  • Proton HeartPet — Proton HeartPet is the company in the field of pet intelligent medical care.
  • Cantoni Therapeutics
Show all investments...

6K Venture Capital
VC Fund · 1 investments in Belgium Life Science startups

6K Venture Capital operates as a venture capital firm.

Show more...

Investment focus

  • Industry: Medical, Software, Health Care
  • Stage:Seed, Series A
  • Geography: Panama, Belgium

Investor stats

  • Total investments: 2
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Rise Of Defenders — Rise of Defenders is a very interesting Metaverse NFT game, you can use your creativity and tactical thinking to become an excellent player and receive extremely attractive rewards.
  • Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
Show all investments...

WING by Digital Wallonia
VC Fund · Liège, Liege, Belgium · 1 investments in Belgium Life Science startups

W.IN.G by Digital Wallonia invests in SAAS, advanced tech and deep tech startups (AI, drones, medtech, IOT,...). W.IN.G brings smart money by helping startups by bi-weekly interactions and providing an operating teams (seasonal entrepreneurs being hands-on with the portfolio).

Show more...

Investment focus

  • Industry: Software, Health Care, Information Technology
  • Stage:Seed, Series A, Convertible Note
  • Geography: Belgium

Investor stats

  • Total investments: 34
  • Round size: Seed $346k–$1.9M; Series A $1.1M–$11M; Convertible Note $219k–$555k
  • Lead/follow: 26% lead, 74% follow

Portfolio highlights

  • IONNYK — IONNYK is a new medium of art photography, containing millions of tiny ink capsules.
  • MYOCENE — Myocene is a Liège-based sports technology company which creates unique and innovative devices for measuring muscle fatigue and performance.
  • Soil Capital Belgium — Discover Europe's first certified, multi-national carbon farming programme that rewards regenerative agriculture.
Show all investments...

Epimède SA
VC Fund · 1 investments in Belgium Life Science startups

Epimède SA

Show more...

Investment focus

  • Industry: Biotechnology, Medical, Health Care
  • Stage:Series B, Series C, Series D
  • Geography: Belgium, The Netherlands

Investor stats

  • Total investments: 5
  • Round size: Series B $12M–$23M
  • Lead/follow: 40% lead, 60% follow

Portfolio highlights

  • Imcyse — Imcyse is a clinical stage biopharmaceutical company pioneering the development of a new class of active specific immunotherapies for the treatment of severe chronic autoimmune diseases. The company’s unique technology platform allows it to locally target immune cells involved in the destruction of the diseased organ. This platform is based on theadministration of Imotopes™, which are specifically modified peptides, allowing for the generation of cytolytic CD4 T-cells, that specifically eliminate antigen-presenting cells and autoantigen specific lymphocytes. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no current therapeutic alternative and to potentially cure patients without impairing immune defense. The company has established proof of concept in several indications and has completed its first clinical trial in type 1 diabetes with promising results. Beyond type 1 diabetes, Imcyse is developing a pipeline of Imotopes™ for the treatment of several autoimmune diseases.
  • Ncardia — At Ncardia, we believe that human stem cell technology will help get better therapies to patients faster.
  • Endo Tools Therapeutics — Endo Tools Therapeutics is dedicated to the development of innovative devices that provide therapeutic interventions for gastric conditions
Show all investments...

Korys
VC Fund · Halle, Vlaams-Brabant, Belgium · 1 investments in Belgium Life Science startups

Korys is the name chosen by the Colruyt family for their investment structure. The name Korys is derived from the Latin word for hazelnut tree – Corylus - which is at the origin of the Colruyt name.Their multi-disciplinary approach enables us to create a well-balanced, diversified portfolio of listed stocks and bonds, private equity funds, anddirect participations in small and medium-sized companies. Through their investments, they aim to make a positive impact on people and the planet, while generating attractive returns. A “three P” approach (People, Planet, Profit) forms the cornerstone of their investment strategy. They invest for the long term, as they realize that it takes time to achieve the sustainable impact they are aiming for. They focus their investments in sectors in which they have built substantial expertise as a team: Cleantech, consumer goods & retail and life sciences.

Show more...

Investment focus

  • Industry: Biotechnology, Renewable Energy, Information Technology
  • Stage:Series B, Series A
  • Geography: Belgium, The Netherlands, Germany

Investor stats

  • Total investments: 48
  • Round size: Series A $3.9M–$13M; Series B $6.4M–$50M
  • Lead/follow: 46% lead, 54% follow

Portfolio highlights

  • Entrix — Entrix is an optimisation and trading platform for grid-scale battery storage that accelerates the transition towards a clean energy future. Our mission is to enable the most effective use of green energy and to ensure the reliability of the future energy system. We provide state-of-the-art technology and services to both asset owners and potentialinvestors across the globe.
  • OroraTech — From safeguarding forests and ecosystems to protecting communities and critical assets, OroraTech's advanced technology and reliable insights address challenges, mitigate risks, and drive meaningful impact.
  • Ona Therapeutics — Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine.
Show all investments...

UCB Ventures
VC Fund · Brussels, Brussels Hoofdstedelijk Gewest, Belgium · 1 investments in Belgium Life Science startups

UCB Ventures is a €150 million strategic corporate venture fund

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Seed
  • Geography: United States, Belgium, Spain

Investor stats

  • Total investments: 20
  • Round size: Seed $1.8M–$6.6M; Series A $6.6M–$75M; Series B $9.4M–$135M
  • Lead/follow: 40% lead, 60% follow

Portfolio highlights

  • SonoThera — Explore therapeutic ultrasound for non-invasive, targeted genetic medicine delivery that improves precision and biodistribution. Learn more.
  • Splice Bio — Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
  • Neurona Therapeutics — Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.
Show all investments...

SFPI-FPIM
VC Fund · Brussels, Brussels Hoofdstedelijk Gewest, Belgium · 1 investments in Belgium Life Science startups

The Federal Holding and Investment Company (SFPI-FPIM) centrally manages the federal government’s shareholdings, cooperates with the government on specific projects and pursues its own investment policy in the interests of the Belgian economy.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series B, Series A
  • Geography: Belgium, United States, The Netherlands

Investor stats

  • Total investments: 40
  • Round size: Series A $4.4M–$46M; Series B $11M–$75M
  • Lead/follow: 15% lead, 85% follow

Portfolio highlights

  • Qpinch — Our patented QHT - Qpinch Heat Transformer - technology recovers and transforms waste heat into carbon neutral process heat.
  • Axelera AI — Axelera AI is developing a game-changing hardware and software platform for AI.Incubated in 2019 by the emerging technologies leader Bitfury and joined by the leading nano-technology group imec in early 2020, Axelera AI launched as a new company in 2021. Headquartered in the AI Innovation Center of the High Tech Campus in Eindhoven, Axelera AIhas R&D offices in Belgium, Switzerland, and Italy. Its team of experts in AI software and hardware hail from top AI firms and Fortune 500 companies.
  • Tangent Works — Create predictive models in seconds for faster and better forecasting & anomaly detection with TIM InstantML.
Show all investments...

BioGeneration Ventures
VC Fund · Naarden, Noord-Holland, The Netherlands · 1 investments in Belgium Life Science startups

Shaping new life-science ventures.

Show more...

Investment focus

  • Industry: Biotechnology, Therapeutics, Health Care
  • Stage:Series A, Seed
  • Geography: The Netherlands, United States, Belgium

Investor stats

  • Total investments: 63
  • Round size: Seed $1.1M–$50M; Series A $5.3M–$86M
  • Lead/follow: 29% lead, 71% follow
  • Last fund: May invest from a new fund soon — raised $148M in 2021

Portfolio highlights

  • Dualyx — Dualyx engages in the discovery and development of biologicals for the treatment of autoimmune and rare diseases.
  • Azafaros — Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.
  • Complement Therapeutics — Turning powerful new Complement System insights into innovative treatments Developing the next generation of complement medicines [chevron-down] Turning powerful new Complement System insights into innovative treatments Developing the next generation of complement medicines [chevron-down] Geographic atrophy (late dry age-related macular degeneration) is a chronic eye condition that affects millions - and for which there is
Show all investments...

Nivelinvest
VC Fund · Louvain-la-neuve, Vlaams-Brabant, Belgium · 1 investments in Belgium Life Science startups

Nivelinvest is a venture capital firm based in Belgium that finances seed stage investments of Small and Medium Enterprises.

Show more...

Investment focus

  • Industry: Biotechnology, iOS, Sports
  • Stage:Series A, Seed
  • Geography: Belgium, United States

Investor stats

  • Total investments: 6
  • Round size: Series A $6.6M–$31M
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • e-peas — Discover e-peas, pioneer of the Ambient IoT concept since 2014, which offers the most efficient energy harvesting pmics on the market to make your devices more energy self-sufficient: AEMs.
  • A-Mansia Biotech — A-Mansia Biotech is a developer of products based on the properties of the Akkermansia muciniphila (A. muciniphila) bacterium. The company's nutritional supplement based on a gut bacterium called Akkermansia, the population of microorganisms housed in the gastrointestinal tract. A. muciniphila is located in the mucus layer covering theintestinal epithelium, which allows the bacterium to establish a close cross-talk with the host.
  • Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
Show all investments...

Nausicaa Ventures
VC Fund · Mont-saint-guibert, Brabant Wallon, Belgium · 1 investments in Belgium Life Science startups

A multi-industry early stage venture capital fund Nausicaa Ventures is an early stage investment fund organisation focused on investment rounds between EUR 1 and 4 million. Nausicaa Ventures was created in 2009 by bringing together 35 private investors and selected institutional investors, such as the European Investment Fund or ING Bank, under the management of ...

Show more...

Investment focus

  • Industry: Software, CRM, Big Data
  • Stage:Series B
  • Geography: Belgium

Investor stats

  • Total investments: 2
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • NGDATA — NGDATA is the consumer intelligence management solutions company that empowers enterprises seeking greater customer lifetime value to drive continuous, actionable insights to enable sales and increase customer loyalty.The company does this through its unique combination of Big Data management and machine learning technologies in a singleintegrated solution.Recently named one of Bank Systems and Technology Magazine’s “Top 7 Big Data Players to Watch,” NGDATA is headquartered in Ghent, Belgium with offices in New York City and San Francisco. The company provides solutions to data-driven sectors such as financial services, retail and media/publishing.
  • Ovizio — Ovizio develops digital holographic interferometric microscopy products. It builds 4D microscopic imaging devices and software based on digital holographic microscopy. Ovizio offers oLine 4D, a research and development, and diagnostic desktop device that is used without specific sample preparation, as well as with automatic compensation ofscratches or distortions on the sample support; iLine 4D, a multipurpose device for applications, such as inline or online flow monitoring or direct monitoring of cell cultures in bioreactors; and OsOne software for visualization, analysis, and archiving of images captured by the imaging devices. It also provides ILine F, a device that captures suspension cell culture process in real time; iLine M, an instrument that monitors cell confluence in multi layer vessels; iLine S, an equipment that monitors reproducibility of fragile cell; and QMod, a holographic and fluorescene microscopy. Scientists in the areas of pharmaceutical and biotech research and development use the products of Ovizio. Philip Mathuis and Serge Jooris founded it in 2009, with its headquarters in Brussels in Belgium.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Fonds Vives II (University of Louvain, UCL)
VC Fund · 1 investments in Belgium Life Science startups

Fonds Vives II (University of Louvain, UCL)

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Seed
  • Geography: Belgium, United States

Investor stats

  • Total investments: 5
  • Round size: Series A $9.9M–$14M; Series B $6.6M–$75M
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Virovet — Antiviral drugs and thermostable vaccines for livestock
  • Sunrise — Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems.
  • ITeos Therapeutics — iTeos Therapeutics is pioneering the discovery and development of highly differentiated immuno-oncology therapeutics for cancer patients.
Show all investments...

VIVES Funds
VC Fund · Wavre, Brabant Wallon, Belgium · 1 investments in Belgium Life Science startups

VIVES is a seed capital fund initiated by UCLouvain which invests in companies developing disruptive innovations with a positive societal impact.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Seed, Series A, Series B
  • Geography: Belgium, France, Switzerland

Investor stats

  • Total investments: 9
  • Round size: Seed $2.9M–$5.5M; Series A $18M–$57M; Series B $34M–$132M
  • Lead/follow: 22% lead, 78% follow

Portfolio highlights

  • Generare — Generare decodes microbial genomes to generate novel, high-quality molecular data for drug discovery. 200+ new molecules characterized and growing.
  • Sunrise — Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems.
  • Nuclidium — NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics.
Show all investments...

Ifoghas Investments
VC Fund · 1 investments in Belgium Life Science startups

Ifoghas Investments operates as an investment firm.

Show more...

Investment focus

  • Industry: Medical, Health Care, Life Science
  • Stage:Series A
  • Geography: Belgium

Investor stats

  • Total investments: 1
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
Show all investments...

Longwood Fund
VC Fund · Boston, Massachusetts, United States · 1 investments in Belgium Life Science startups

Longwood creates and invests in science-based companies that develop novel solutions for important medical problems

Show more...

Investment focus

  • Industry: Biotechnology, Therapeutics, Health Care
  • Stage:Series A, Series B, Series C
  • Geography: United States, United Kingdom, Italy

Investor stats

  • Total investments: 75
  • Round size: Series A $16M–$100M; Series B $25M–$152M; Series C $17M–$100M
  • Lead/follow: 15% lead, 85% follow
  • Last fund: Likely still investing — fund raised in 2023

Portfolio highlights

  • ImmuneID — SANTOTO4D adalah situs togel WLA resmi terpercaya dengan pasaran lengkap sistem keamanan tinggi dan layanan cepat Daftar sekarang dan raih jackpot besar
  • Vertero — Axial Therapeutics is a biotechnology company fundamentally changing the treatment of neurological diseases and disorders by harnessing groundbreaking science in the microbiome-gut-brain axis.
  • Immunitas Therapeutics — Immunitas is unlocking human immunology using novel single cell analyses to develop targeted therapeutics for patients with challenging, complex cancers. Translating findings from laboratory research to meaningful clinical advances in humans is a longstanding challenge in the oncology field. Immunitas was founded to directly address this problemand unlock a variety of novel drug targets based on discovery rooted in human biology. They are pursuing this goal with a team of pioneers in these areas across their scientific founders, management, and investors.At Immunitas, they employ a single cell sequencing platform to dissect the biology of immune cells in human tumors. Their focus on human samples allows us to start with and stay closer to the most relevant and translatable biology for patients and accelerates the pace of their research. They are identifying novel, exciting oncology targets and, importantly, developing key biomarkers to guide the selection of patients who may benefit from their new drugs. They are leveraging expertise in antibody discovery and engineering to create powerful therapies that modulate these targets, and are currently advancing a number of programs toward early human studies.
Show all investments...

Galapagos
VC Fund · Mechelen-bovelingen, Limburg, Belgium · 1 investments in Belgium Life Science startups

We are scientists, entrepreneurs, and pioneers united around a single purpose: to transform patient outcomes through life-changing science and innovation for more years of life and quality of life for people around the world.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Life Science
  • Stage:Seed, Series A, Series C
  • Geography: France, Belgium, United States

Investor stats

  • Total investments: 5
  • Round size: Series A $52M–$125M
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Terratis — Terratis is a French company that uses the Sterile Insect Technique (SIT) to reduce the populations of tiger mosquitoes and agricultural pests. Their mission is to diminish harmful insect populations effectively on a large scale using a scientific, innovative, ecological, and efficient approach.
  • Third Arc Bio — Third Arc Bio is advancing antibody technology by unlocking the powerful biology of immune synapses to address solid tumors and autoimmune diseases.
  • Coultreon Biopharma — Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.Coultreon Biopharma employs extensive experience in disease biology, drug development, and translational science to identify the optimum treatment approach for addressing underlying illness biology withbest-in-class therapeutics.
Show all investments...

Finchley Healthcare Ventures
VC Fund · 1 investments in Belgium Life Science startups

Finchley Healthcare Ventures is an investment firm invest in venture capital funds specializing in life sciences, leveraging their expertise and network to access a diverse range of investment opportunities.

Show more...

Investment focus

  • Industry: Biotechnology, Biopharma, Life Science
  • Stage:Series B, Series A
  • Geography: United States, Belgium

Investor stats

  • Total investments: 4
  • Round size: Series B $67M–$120M
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Coultreon Biopharma — Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.Coultreon Biopharma employs extensive experience in disease biology, drug development, and translational science to identify the optimum treatment approach for addressing underlying illness biology withbest-in-class therapeutics.
  • Triana Biomedicines — Triana Biomedicines is building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high- resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated thebest-in-class platform and initiated multiple programs across different disease areas.
  • Cartography Biosciences — Cartography is shaping a world in which cancer immunotherapies are designed around and directed toward the safest and most effective targets.
Show all investments...

Balyasny Asset Management
VC Fund · Chicago, Illinois, United States · 1 investments in Belgium Life Science startups, 21 in the past 12 months

Balyasny is a multi-strategy asset management firm. Our goal is to provide consistent, uncorrelated returns in all market environments.

Show more...

Investment focus

  • Industry: Biotechnology, FinTech, Analytics
  • Stage:Series D, Series A, Series C
  • Geography: United States, China, Sweden

Investor stats

  • Total investments: 46
  • Round size: Series A $6.1M–$179M; Series C $50M–$350M; Series D $35M–$225M
  • Lead/follow: 7% lead, 93% follow
  • Last fund: May invest from a new fund soon — last raise in 2018

Portfolio highlights

  • Quince Therapeutics — Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currentlytesting several potential lead therapeutics in preclinical studies.
  • Coultreon Biopharma — Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.Coultreon Biopharma employs extensive experience in disease biology, drug development, and translational science to identify the optimum treatment approach for addressing underlying illness biology withbest-in-class therapeutics.
  • Cellectar Biosciences — Cellectar Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer.
Show all investments...

Novo Holdings
VC Fund · Hellerup, Hovedstaden, Denmark · 1 investments in Belgium Life Science startups

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: United States, Denmark, United Kingdom

Investor stats

  • Total investments: 350
  • Round size: Series A $9M–$125M; Series B $12M–$135M; Series C $30M–$118M
  • Lead/follow: 41% lead, 59% follow
  • Last fund: May invest from a new fund soon — raised $165M in 2018

Portfolio highlights

  • Verana Health — Verana Health is assembling the largest clinical databases in medicine to empower physicians and accelerate research for patients.
  • SCHOTT Poonawalla — SCHOTT Poonawalla is a manufacturer of pharmaceutical containers, made of neutral glass tubing. The company provides parenteral packaging systems crafted from tubular glass, serving the pharmaceutical industry with a broad range of products including vials, pre-fillable syringes, ampoules, and cartridges.
  • Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
Show all investments...

invest.bw
VC Fund · Louvain-la-neuve, Vlaams-Brabant, Belgium · 1 investments in Belgium Life Science startups

invest.bw is a venture capital firm.

Show more...

Investment focus

  • Industry: Electronics, Biotechnology, Manufacturing
  • Stage:Seed, Pre-Seed, Series A
  • Geography: Belgium, United States

Investor stats

  • Total investments: 8
  • Round size: Seed $2.9M–$43M
  • Lead/follow: 13% lead, 87% follow

Portfolio highlights

  • neuroClues — An easy-to-use eye-tracking environment to help practitioners instantaneously quantify their clinical exam
  • Vertical Compute — Vertical Compute offers chiplet-based technology that cuts data movement to achieve up to 80% energy savings.
  • ARK Capture Solutions — ARK Capture Solutions is a cleantech company that specializes in decarbonization solutions to record low energy consumption.
Show all investments...

Opdorp Finance BVBA
VC Fund · 1 investments in Belgium Life Science startups

Opdorp Finance BVBA

Show more...

Investment focus

  • Industry: Life Science, Data Integration, Data Visualization
  • Stage:Series A
  • Geography: Belgium

Investor stats

  • Total investments: 1
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • ONTOFORCE — ONTOFORCE creates and implements pioneering semantic search technology for information management. Our user-friendly data search platform DISQOVER builds uniquely intelligent links between heterogeneous data sources, allowing everybody to become a data scientist.
Show all investments...

Life Science VC funding in Belgium at a glance

Stats across 39 deals from 62 investors.

62
investors
in Belgium Life Science startups
39
deals
in Belgium Life Science startups
$3.5M
median round
in Belgium Life Science startups
42%
lead investors
lead at least one round
26%
Seed
most common funding stage

Access all 62 VC funds in Belgium Life Science startups.

Open List

FAQ

Is Shizune data fresh/accurate?

Shizune has monitored hundreds of funding sources since 2020.

Our investor database is updated every day, so investor data is always fresh.

All metrics are calculated from confirmed public rounds, so the data is accurate.

Can I download investor list?

To download the Life Science VC Funds in Belgium investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.

You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.

Can I access investor database?

To access all 62 VC funds investing in Belgium Life Science startups and 48,091+ more investors, create a Shizune account.

Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.

The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.

You can enrich with email and download the data.

Does Shizune have investor emails and contacts?

Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.

To guarantee the highest discovery rate, we search across 20+ contact search tools.

To maximize delivery rate and reduce bounce rate, we validate emails.

You can enrich your investor list with Shizune. Download it too.

What is Shizune?

Shizune is a 48,091 investor database updated daily.

With Shizune you can:

  • browse the database
  • use smart matching
  • enrich with emails
  • download

All you need to find investors for your startup.

Who is Shizune for?

Shizune is built for startup founders by startup founders.

If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.

Is Shizune free?

Shizune is free forever. You can search and browse investors for free.

Email search and export are paid features.

For full info, visit our pricing.

Who built Shizune?

Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.

Contact 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!

More investor lists

Broader lists